Analysts await BIND Therapeutics, Inc. (NASDAQ:BIND) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.44 EPS, up 15.91% or $0.07 from last year’s $-0.51 per share.

At the moment 4 analysts are watching BIND Therapeutics, Inc. (NASDAQ:BIND), 2 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 2 analysts have a mean sales target of 2.56 million. For the quarter ending Jun-16, 2 analysts have a mean sales target of 2.57 million whilst for the year ending Dec-16, 4 analysts have a mean target of 13.45 million.

In terms of earnings per share, 2 analysts have a -0.47 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.41 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -1.97 EPS.

The biggest institutional shareholders in BIND Therapeutics, Inc. include Polaris Venture Management Co. V,LLC which owns 2 million shares in the company valued at $9.00 million. Heights Capital Management Inc is the second biggest holder with 1 million shares currently valued at 9.45 million whilst Sabby Management LLC has 821 K million shares valued at 1.88 million.

Total shares held by institutions as of the most recent company filings are 6,196,129 with a reported 90,549 bought and 805,315 sold. These holdings make up 29.81% of the company’s outstanding shares.

The stock increased 5.98% or $0.11 during the last trading session, hitting $7.98. BIND Therapeutics, Inc. (NASDAQ:BIND) has risen 37.22% over the past 6 months and is uptrending.